دورية أكاديمية
أعرض في EDS

Impact of HIV-Related Immune Impairment of Yellow Fever Vaccine Immunogenicity in People Living with HIV-ANRS 12403.

التفاصيل البيبلوغرافية
العنوان: Impact of HIV-Related Immune Impairment of Yellow Fever Vaccine Immunogenicity in People Living with HIV-ANRS 12403.
المؤلفون: Caetano DG; Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil., Toledo TS; Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil., de Lima ACS; Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil., Giacoia-Gripp CBW; Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil., de Almeida DV; Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil., de Lima SMB; Departamento de Desenvolvimento Experimental e Pré-Clínico (DEDEP), Bio-Manguinhos/Fiocruz, Rio de Janeiro 21040-900, Brazil., Azevedo AS; Laboratório de Análise Imunomolecular (LANIM), Bio-Manguinhos/Fiocruz, Rio de Janeiro 21040-900, Brazil., Morata M; Instituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil., Grinsztejn B; Instituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil., Cardoso SW; Instituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil., da Costa MD; Laboratório de Pesquisa em Imunização e Vigilância em Saúde (LIVS), Instituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil., Brandão LGP; Laboratório de Pesquisa em Imunização e Vigilância em Saúde (LIVS), Instituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil., Bispo de Filippis AM; Laboratório de Flavivírus, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil., Scott-Algara D; Lymphocyte Cell Biology Unit, Pasteur Institute, 75015 Paris, France., Coelho LE; Instituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil., Côrtes FH; Laboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil.
المصدر: Vaccines [Vaccines (Basel)] 2024 May 25; Vol. 12 (6). Date of Electronic Publication: 2024 May 25.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG
مستخلص: The yellow fever (YF) vaccine is one of the safest and most effective vaccines currently available. Still, its administration in people living with HIV (PLWH) is limited due to safety concerns and a lack of consensus regarding decreased immunogenicity and long-lasting protection for this population. The mechanisms associated with impaired YF vaccine immunogenicity in PLWH are not fully understood, but the general immune deregulation during HIV infection may play an important role. To assess if HIV infection impacts YF vaccine immunogenicity and if markers of immune deregulation could predict lower immunogenicity, we evaluated the association of YF neutralization antibody (NAb) titers with the pre-vaccination frequency of activated and exhausted T cells, levels of pro-inflammatory cytokines, and frequency of T cells, B cells, and monocyte subsets in PLWH and HIV-negative controls. We observed impaired YF vaccine immunogenicity in PLWH with lower titers of YF-NAbs 30 days after vaccination, mainly in individuals with CD4 count <350 cells/mm 3 . At the baseline, those individuals were characterized by having a higher frequency of activated and exhausted T cells and tissue-like memory B cells. Elevated levels of those markers were also observed in individuals with CD4 count between 500 and 350 cells/mm 3 . We observed a negative correlation between the pre-vaccination level of CD8 + T cell exhaustion and CD4 + T cell activation with YF-NAb titers at D365 and the pre-vaccination level of IP-10 with YF-NAb titers at D30 and D365. Our results emphasize the impact of immune activation, exhaustion, and inflammation in YF vaccine immunogenicity in PLWH.
References: J Immunol. 2009 Jan 15;182(2):890-901. (PMID: 19124732)
AIDS. 2004 Mar 26;18(5):825-7. (PMID: 15075524)
Nature. 2006 Sep 21;443(7109):350-4. (PMID: 16921384)
Immunotherapy. 2015;7(12):1273-92. (PMID: 26289364)
PLoS Pathog. 2016 Jan 07;12(1):e1005349. (PMID: 26741490)
AIDS. 2014 Jul 31;28(12):1749-58. (PMID: 24871455)
Blood. 2010 Dec 16;116(25):5571-9. (PMID: 20837780)
Immunol Rev. 2019 Nov;292(1):149-163. (PMID: 31883174)
J Travel Med. 2022 Dec 27;29(8):. (PMID: 35285913)
AIDS. 2015 Oct 23;29(16):2099-108. (PMID: 26544576)
Nat Immunol. 2009 Jan;10(1):29-37. (PMID: 19043418)
Curr HIV Res. 2010 Sep;8(6):461-6. (PMID: 20636276)
Front Immunol. 2017 Mar 13;8:272. (PMID: 28348563)
Clin Infect Dis. 2009 Mar 1;48(5):659-66. (PMID: 19191654)
J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):360-7. (PMID: 22267015)
NPJ Vaccines. 2022 Dec 19;7(1):170. (PMID: 36535976)
J Immunol. 2008 Jul 15;181(2):1199-206. (PMID: 18606673)
J Clin Invest. 2011 Jul;121(7):2614-24. (PMID: 21633172)
Clin Infect Dis. 2020 Apr 10;70(8):1636-1642. (PMID: 31131858)
J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):137-47. (PMID: 19131896)
J Infect Dis. 2016 Aug 1;214(3):390-8. (PMID: 27122593)
Sci Rep. 2022 Apr 21;12(1):6569. (PMID: 35449171)
PLoS Pathog. 2014 Aug 28;10(8):e1004345. (PMID: 25167059)
J Virol. 2014 Dec;88(23):13836-44. (PMID: 25253339)
J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):189-95. (PMID: 26361176)
J Virol. 2007 Dec;81(24):13904-15. (PMID: 17928341)
Nature. 2000 Oct 5;407(6804):636-42. (PMID: 11034213)
J Venom Anim Toxins Incl Trop Dis. 2018 Aug 25;24:20. (PMID: 30158957)
J Med Assoc Thai. 2002 Jan;85(1):131-4. (PMID: 12075714)
Front Immunol. 2021 Jun 04;12:647688. (PMID: 34149690)
J Clin Invest. 2014 Jul;124(7):3147-58. (PMID: 24911151)
J Acquir Immune Defic Syndr. 2009 Dec;52(5):553-9. (PMID: 19950429)
Blood. 2012 Nov 29;120(23):4599-608. (PMID: 23065151)
Annu Rev Pathol. 2011;6:223-48. (PMID: 21034222)
Immunol Rev. 2017 Jan;275(1):33-48. (PMID: 28133792)
J Infect Dis. 2011 Oct 15;204(8):1217-26. (PMID: 21917895)
J Immunol. 2013 Sep 1;191(5):2194-204. (PMID: 23918986)
Retrovirology. 2014 Sep 11;11:76. (PMID: 25213015)
AIDS. 2018 Oct 23;32(16):2291-2299. (PMID: 30096071)
Nat Med. 2006 Oct;12(10):1198-202. (PMID: 16917489)
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):161-7. (PMID: 23314411)
AIDS. 2013 May 15;27(8):1209-17. (PMID: 23343911)
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14733-8. (PMID: 20679213)
PLoS Negl Trop Dis. 2022 Feb 7;16(2):e0010133. (PMID: 35130278)
Clin Infect Dis. 2018 Mar 19;66(7):1099-1108. (PMID: 29140432)
PLoS One. 2020 Feb 5;15(2):e0228745. (PMID: 32023301)
PLoS One. 2014 Aug 05;9(8):e104235. (PMID: 25093660)
J Clin Invest. 2014 Jul;124(7):3252-62. (PMID: 24892810)
PLoS Med. 2014 May 06;11(5):e1001638. (PMID: 24800812)
Clin Infect Dis. 2000 Sep;31(3):E7-8. (PMID: 11017859)
J Clin Virol. 2015 Mar;64:160-73. (PMID: 25453327)
AIDS. 2005 Nov 18;19(17):1947-55. (PMID: 16260900)
Virology. 2010 Feb 5;397(1):7-13. (PMID: 19962720)
AIDS Patient Care STDS. 2008 Jan;22(1):65-70. (PMID: 18095834)
N Engl J Med. 2019 Aug 1;381(5):444-454. (PMID: 29443626)
Wellcome Open Res. 2019 Nov 20;4:182. (PMID: 31984244)
Annu Rev Immunol. 2003;21:265-304. (PMID: 12524385)
Front Immunol. 2021 Jul 22;12:699895. (PMID: 34367161)
J Exp Med. 2008 Aug 4;205(8):1797-805. (PMID: 18625747)
AIDS. 2015 Feb 20;29(4):463-71. (PMID: 25630041)
BMC Infect Dis. 2010 Sep 22;10:280. (PMID: 20860822)
Nat Rev Immunol. 2020 Mar;20(3):173-185. (PMID: 31676858)
Mediators Inflamm. 2017;2017:6825493. (PMID: 29209103)
Immunity. 2019 May 21;50(5):1132-1148. (PMID: 31117010)
Clin Sci (Lond). 2022 Jan 14;136(1):61-80. (PMID: 34985109)
Biologicals. 2012 Nov;40(6):399-404. (PMID: 23034357)
J Immunol. 2007 Jun 15;178(12):8212-20. (PMID: 17548660)
PLoS Pathog. 2016 Jul 14;12(7):e1005661. (PMID: 27415828)
Sci Rep. 2017 Aug 7;7(1):7385. (PMID: 28785067)
Blood. 2003 Apr 1;101(7):2711-20. (PMID: 12433688)
Curr HIV/AIDS Rep. 2010 Feb;7(1):4-10. (PMID: 20425052)
AIDS. 2023 Dec 1;37(15):2319-2329. (PMID: 37650759)
Rev Saude Publica. 2004 Oct;38(5):671-8. (PMID: 15499438)
J Immunol. 2004 Aug 1;173(3):2184-9. (PMID: 15265956)
J Infect Dis. 2009 Oct 15;200(8):1212-5. (PMID: 19728788)
Pediatr Infect Dis J. 1997 Dec;16(12):1177-9. (PMID: 9427466)
PLoS Biol. 2004 Feb;2(2):E20. (PMID: 14966528)
J Immunol. 2003 Jan 15;170(2):686-94. (PMID: 12517929)
J Exp Med. 2008 Nov 24;205(12):2763-79. (PMID: 19001139)
معلومات مُعتمدة: Project 12403 Agence Nationale de Recherches sur le Sida et les Hépatites Virales; Chamada CNPq/Fiocruz N8 16/2017 PROEP/PEC / #420674/2017-9 Presidência da Fundação Oswaldo Cruz/ Vice-presidência de Pesquisa e Coleções Biológicas VPPCB/Fiocruz
فهرسة مساهمة: Keywords: B cells; HIV-1; immune activation; immune exhaustion; inflammation; yellow fever vaccine
تواريخ الأحداث: Date Created: 20240627 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC11209244
DOI: 10.3390/vaccines12060578
PMID: 38932307
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-393X
DOI:10.3390/vaccines12060578